Carregant...
Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents i...
Guardat en:
| Publicat a: | Contemp Oncol (Pozn) |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Termedia Publishing House
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4268992/ https://ncbi.nlm.nih.gov/pubmed/25520572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2014.43153 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|